Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 and closed at $28.50 on its first trading day on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, the Shanghai-based firm announced.
The company priced its initial public offering at $17.00 per share, but investor demand pushed the stock significantly higher by the closing bell. Shares finished the session at $28.50, representing a gain of roughly 68 percent from the IPO price — a strong first-day performance by any measure in the current biotech market environment.
Read more Build-A-Bear Workshop Faces Securities Class Action Lawsuit →
Windward Bio focuses on immunology, an area of drug development that has drawn sustained investor interest given the broad therapeutic potential of immune-modulating treatments across oncology, autoimmune disorders, and infectious disease. The company's listing adds to a growing cohort of Asia-linked biotechs seeking access to U.S. capital markets through Nasdaq.
Qiming Venture Partners, one of the most active venture capital firms investing in Chinese life sciences, counts Windward Bio among its portfolio holdings. The firm's backing signals institutional confidence in the biotech's pipeline ahead of what are likely to be capital-intensive late-stage clinical trials.
Continue reading at All Financial Services & Investing.